Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Olay Vitamins launch

This article was originally published in The Tan Sheet

Executive Summary

Procter & Gamble and Pharmavite announce supplement collection begins selling nationally Sept. 23. Print ads currently appearing in national magazines; TV ads slated to break on major networks in October. Advertising budget was not announced. P&G spent $165 mil. on ads for the Olay brand last year according to TNS Media Intelligence. Olay vitamins is made up of two product lines, featuring 15 items in total, including vitamins promoting health and wellness as well as those designed for skin care concerns such as "even tone" and "smooth texture" (1"The Tan Sheet" June 16, 2003, p. 12). Prices range from $7.99 to $24.99...

You may also be interested in...



Olay Vitamins Cross-Promotion With P&G Skin Care Line Planned

Pharmavite will support the launch of Olay Vitamins with television and print ads, in-store merchandising and cross-promotions with Olay skin care products to garner new vitamin users, the firm said

Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Gel

Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.

US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says

The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel